Vistagen Therapeutics, Inc. (VTGN) fundamentals score
Vistagen Therapeutics is a late clinical-stage therapeutics company focused on developing and potentially commercializing new medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 5.3 out of 10, Mixed fundamentals
- Growth: 6.8/10
- Profitability: 3.3/10
- Financial health: 5.5/10
- Earnings quality: 4.5/10
- Valuation: 6.6/10
Scores are calculated from Vistagen Therapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10